Summary:
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Systemic Lupus Erythematosus.
Qualified Participants Must:
• Complete a minimum of 9 visits over the course of 40 weeks with compensation for each completed visit.
Qualified Participants May Receive:
A chance to receive Obexelimab and compensation for their time.